echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Nature Communications: Fat cells destroy the transformation process of acute lymphoblastic leukemia, which is conducive to tumor survival and persistence

    Nature Communications: Fat cells destroy the transformation process of acute lymphoblastic leukemia, which is conducive to tumor survival and persistence

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The specific niche adaptation that promotes survival of primary disease and acute lymphoblastic leukemia (ALL) after induction chemotherapy is not yet known
    .


    Therefore, an article published by a foreign research team in the journal Nature Communications demonstrated the dynamic evolution of bone marrow (BM) fat cells in the pathogenesis and treatment of ALL


    The specific niche adaptation that promotes survival of primary disease and acute lymphoblastic leukemia (ALL) after induction chemotherapy is not yet known


    FIG FIG 1: 1: Fat niche BM cells in the pathogenesis and treatment of dynamic remodeling ALL adipocytes BM niche dynamic remodeling in the pathogenesis and treatment of ALL

    Figure 2: ALL disrupts the function and lineage activation of the adipocyte precursor mesenchymal stromal cell (MSC) population

    FIG.
    FIG.
    2: 2: ALL destroy the adipose precursor cells of mesenchymal stromal cells (MSC) function and lineage population started ALL destroy the adipose precursor cells of mesenchymal stromal cells (MSC) function and lineage start Group

    Figure 3: Adipocytes create a tumor suppressor site in B-ALL

    Figure 3: Adipocytes create a tumor suppressor site in B-ALL Figure 3: Adipocytes create a tumor suppressor site in B-ALL

    Figure 4: Adipocyte niche restricts protein synthesis in ALL through atypical factors

    FIG.
    FIG.
    4: 4: adipocytes niche protein synthesis is limited by the atypical ALL factor adipocytes niche limit protein synthesis by atypical factors in ALL

    Its dynamic evolution is from cell exhaustion in the niche of primary leukemia to a completely rebuilt state after induction of remission
    .


    Functionally, the fat cells trigger niche ALL cell proliferation and cell still to slow the development direction


    Its dynamic evolution is from cell exhaustion in the niche of primary leukemia to a completely rebuilt state after induction of remission


    The research highlights several important findings


    Original source:

    Original source:

    Heydt, Q.


    Heydt, Q.
    , Xintaropoulou, C.
    , Clear, A.
    et al.
    et al.
    Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence.
    Nat Commun Nat Commun 12,12,  5507 (2021).
    https ://doi.
    org/10.
    1038/s41467-021-25540-4
    https://doi.
    org/10.
    1038/s41467-021-25540-4
    https://doi.
    org/10.
    1038/s41467-021-25540-4 Leave a message here  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.